Synergy Pharmaceuticals (SGYP) has risen sharply, recording gains of 15.51% in the past 4 weeks. However, the stock has corrected -1.78% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 16.14% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 3.55% and the 50-Day Moving Average is 13.06%.The 200 Day SMA reached 37.46%
Synergy Pharmaceuticals (NASDAQ:SGYP): After opening at $5.33, the stock dipped to an intraday low of $5.24 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $5.59 and the buying power remained strong till the end. The stock closed at $5.51 for the day, a gain of 3.77% for the day session. The total traded volume was 2,444,129. The stocks close on the previous trading day was $5.51.
Synergy Pharmaceuticals (SGYP) : 2 investment research analysts covering Synergy Pharmaceuticals (SGYP) have an average price target of $10.75 for the near short term. The highest target price given by the Brokerage Firm to the stock is $15 and the lowest target is $7 for the short term. Analysts expect the variance to be within $6.01 of the average price.
Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.